治疗前心肌18FDG摄取预测心脏结节病患者对免疫抑制治疗的反应
该研究分析96例心脏结节病患者,在免疫抑制治疗前进行18FDG-PET-CT,评估治疗4-6个月后的临床和超声心动图反应。治疗前心肌摄取指数>30和LVEF>40%是治疗反应的独立预测因子,最终模型AUC为0.85,敏感度85.5%,特异度86.4%。
要点
- 治疗前18FDG-PET-CT心肌摄取指数>30与免疫抑制治疗后反应独立相关(HR 1.28,95%CI 1.05-6.12,P=0.010)。
- 治疗前LVEF>40%也是治疗反应的独立预测因子(HR 1.61,95%CI 1.06-7.69,P=0.031)。
- 预测模型区分度良好,AUC为0.85,敏感度85.5%,特异度86.4%。
核心结论
- 治疗前18FDG心肌摄取是心脏结节病患者对免疫抑制治疗临床反应和超声心动图反应的预测因子。
研究设计与样本
- 研究分析了来自肉芽肿性心肌炎登记处的96例连续心脏结节病患者,所有患者在开始免疫抑制治疗前接受18FDG-PET-CT检查,治疗后4至6个月评估反应,最终91例纳入分析。
诊断标准与关键数值
- 临床反应定义为功能分级改善(纽约心脏协会功能分级≥I级)且无室性心律失常和心力衰竭住院。
- 超声心动图反应定义为左心室射血分数(LVEF)改善≥10%,仅在LVEF<50%的患者中评估。
- 完全反应者无残留心肌FDG摄取且满足两项反应标准;部分反应者仅满足1项反应标准或有残留FDG摄取;无反应者不满足临床反应或超声心动图反应标准。
- 摄取指数定义为最大标准化摄取值与18FDG-PET-CT上异常摄取左心室节段数的乘积。
- LVEF>40%预测治疗反应的HR为1.61(95%CI 1.06-7.69,P=0.031),心肌摄取指数>30的HR为1.28(95%CI 1.05-6.12,P=0.010)。
临床应用与阅片要点
- 治疗前18FDG-PET-CT心肌摄取指数可用于预测心脏结节病患者对免疫抑制治疗的反应。
- 治疗前LVEF>40%和心肌摄取指数>30提示治疗反应可能性更高。
- 治疗前心肌摄取指数与免疫抑制治疗后LVEF变化呈强正相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: This study identified predictors of clinical (CR) and echocardiographic response (ER) following immunosuppressive therapy (IST) in patients with cardiac sarcoidosis (CS).
BACKGROUND: IST has been the cornerstone of treatment for patients with CS and active myocardial inflammation. However, there are little data to explain the variable response to IST in CS.
METHODS: Data of 96 consecutive patients with CS from the Granulomatous Myocarditis Registry were analyzed. All patients underwent a 18fluorodeoxy glucose positron emission tomography-computed tomography (18FDG-PET-CT) before initiation of IST. Response was assessed after 4 to 6 months of therapy. CR was defined as an improvement in functional class (New York Heart Association functional class ≥I) and freedom from ventricular arrhythmias and heart failure hospitalizations. ER was defined as an improvement in left ventricular ejection fraction (LVEF) ≥10%. ER was assessed only in patients with a LVEF <50%. Complete responders had no residual myocardial FDG uptake and fulfilled both response criteria. Partial responders fulfilled only 1 response criteria or had residual FDG uptake. Nonresponders did not fulfill either CR or ER criteria. The uptake index (UI) was defined as the product of maximum standardized uptake value and the number of LV segments with abnormal uptake on 18FDG-PET-CT.
RESULTS: Among 91 patients included in the final analysis, 54.9%, 20.9%, and 24.2% of patients were classified as complete and partial responders and nonresponders, respectively. Cox regression analysis (all responders vs. nonresponders) identified the following as independent predictors of response following immunosuppression: LVEF >40% (hazard ratio: 1.61; 95% confidence interval: 1.06 to 7.69; p = 0.031) and myocardial UI >30 (hazard ratio: 1.28; 95% confidence interval: 1.05 to 6.12; p = 0.010). The final model had a good discriminative power (area under the curve [AUC]: 0.85) and predictive accuracy (sensitivity: 85.5%; specificity: 86.4%). Pre-treatment myocardial UI had a strong positive correlation with change in LVEF following immunosuppression.
CONCLUSIONS: Pre-treatment 18FDG myocardial uptake was a predictor of CR and ER response to immunosuppression in patients with CS.
引用
- Subramanian M, Swapna N, Ali AZ, et al. Pre-Treatment Myocardial 18FDG Uptake Predicts Response to Immunosuppression in Patients With Cardiac Sarcoidosis. JACC Cardiovasc Imaging. 2021. PMID: 33454258. doi:10.1016/j.jcmg.2020.11.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。